Navigation Links
PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
Date:10/31/2011

“anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
2. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
3. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
4. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
5. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
6. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
7. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call
9. PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference
10. PAREXEL Invites Public to Listen to Live Webcast of Its Investor Day June 2, 2011
11. PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- UBM Medica US today announced the launch of ... information resource for neurologists and other healthcare providers to ... neurological disorders . The prevalence of ... access to dedicated information for healthcare providers who treat ... , 1 in 6 people are affected ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... 20, 2012   Sysmex America, Inc., a global leader ... today announced its 200th placement of Sysmex WAM ... Laboratory.  Sysmex WAM is now connecting nearly 600 sites ... U.S. and Canada. Sysmex WAM plays a key role ...
... Assured Pharmacy (Pinksheets: APHY), a leading specialty pharmacy group ... present at Anda,s 2012 Supply Chain Symposium on Thursday, ... in Palm Beach Gardens, Florida.  Assured Pharmacy has been ... dispensing controlled substances at pharmacies.   Anda ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 3
(Date:7/23/2014)... July 24, 2014 The routine ... UPMC greatly increases the likelihood of performing the ... and cancer, report researchers from the University of ... , The test, available at the UPMC/UPCI Multidisciplinary ... the chances of patients getting the correct initial ...
(Date:7/23/2014)... 23, 2014 Men and women who ... for life insurance based on national averages. The Quotes ... rates search to its comprehensive tool this year to ... . , Providers that are now underwriting plans ... reviewed in one or two clicks. The intelligent platform ...
(Date:7/23/2014)... Sellafield or Dounreay since the 1990s are not at ... published in the British Journal of Cancer ... Group at the University of Oxford and from Newcastle ... those who were under 25 and living near Sellafield ... cancer incidence from 1991-2006 between those living near these ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 A new ... a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally ... cancers throughout a woman’s body, Bernstein Liebhard LLP reports. ... the Journal of the American Medical Association, looked at ... morcellator at 500 U.S. hospitals from 2006 to 2012. ...
(Date:7/23/2014)... PA) Asking patients if a suspicious skin lesion ... the spot is likely to be cancerous, according to ... of the Department of Dermatology at Temple University School ... JAMA Dermatology on July 23, 2014, found that ... accompanied by itching, while 28.2 percent involve pain. Non-melanoma ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
The Liz Claiborne eyewear collection features feminine, classic, progressive friendly designs that meet the needs of today's women. The high quality frames are modern, but not trendy....
Medicine Products: